Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Sell
15
HEPA Quote, Financials, Valuation and Earnings
Last price:
$0.06
Seasonality move
:
-22.25%
Day range:
$0.06 - $0.07
52-week range:
$0.04 - $56.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.30x
Volume:
25.4K
Avg. volume:
128.7K
1-year change:
-99.89%
Market cap:
$658.6K
Revenue:
--
EPS (TTM):
-$80.50
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Hepion Pharmaceuticals has 2499900% upside to fair value with a price target of -- per share.
HEPA vs. S&P 500
-
Over the past 5 trading days, Hepion Pharmaceuticals has underperformed the S&P 500 by -10.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hepion Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hepion Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hepion Pharmaceuticals reported revenues of --.
Earnings Growth
-
Hepion Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hepion Pharmaceuticals reported earnings per share of -$2.15.
Enterprise value:
-1.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$49.6M | -$37.2M | -$15.4M | -$5.2M | -$1.3M | |
| EBITDA | -$52.8M | -$41.9M | -$15.8M | -$5.8M | -$6.1M | |
| Diluted EPS | -$678.00 | -$470.20 | -$80.50 | -$28.13 | -$2.15 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $117.7M | $89.8M | $45.8M | $15.4M | $6.3M | |
| Total Assets | $123.8M | $95.9M | $49.5M | $16M | $6.3M | |
| Current Liabilities | $2.9M | $6.3M | $9.8M | $2.6M | $935.9K | |
| Total Liabilities | $6.2M | $9.2M | $12.3M | $8.5M | $2.4M | |
| Total Equity | $117.6M | $86.6M | $37.2M | $7.5M | $3.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33M | -$36.3M | -$15.7M | -$3.6M | -$1.1M | |
| Cash From Investing | -$14.1K | -$14.3K | -$600K | -- | -- | |
| Cash From Financing | -$3.1M | $6.3M | $7.8M | $1.8M | $5.3M | |
| Free Cash Flow | -$33M | -$36.3M | -$15.7M | -$3.6M | -$1.1M | |
HEPA
Sector
Market Cap
$658.6K
$34.5M
Price % of 52-Week High
0.11%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-99.89%
-35.15%
Beta (5-Year)
1.688
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.06
200-day SMA
Sell
Level
$14.00
Bollinger Bands (100)
Sell
Level
-1.11 - 3.73
Chaikin Money Flow
Sell
Level
-426.4K
20-day SMA
Sell
Level
$0.07
Relative Strength Index (RSI14)
Sell
Level
34.76
ADX Line
Sell
Level
4.13
Williams %R
Buy
Level
-82.1622
50-day SMA
Sell
Level
$0.12
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Sell
Level
-473.2K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Stock Forecast FAQ
In the current month, HEPA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HEPA average analyst price target in the past 3 months is --.
-
Where Will Hepion Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hepion Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Hepion Pharmaceuticals?
Analysts are divided on their view about Hepion Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hepion Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Hepion Pharmaceuticals's Price Target?
The price target for Hepion Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HEPA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hepion Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HEPA?
You can purchase shares of Hepion Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hepion Pharmaceuticals shares.
-
What Is The Hepion Pharmaceuticals Share Price Today?
Hepion Pharmaceuticals was last trading at $0.06 per share. This represents the most recent stock quote for Hepion Pharmaceuticals. Yesterday, Hepion Pharmaceuticals closed at $0.06 per share.
-
How To Buy Hepion Pharmaceuticals Stock Online?
In order to purchase Hepion Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Microsoft Be a $5 Trillion Stock?
Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…
Where Will C3.ai Stock Be in 1 Year?
C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 12
MiNK Therapeutics [INKT] is up 727.94% over the past day.
Buy
51
NEGG alert for Jul 12
Newegg Commerce [NEGG] is up 74.03% over the past day.
Buy
68
ATRO alert for Jul 12
Astronics [ATRO] is up 16.28% over the past day.
